Laboratorios Farmaceuticos Rovi, S.A. Stock

Equities

ROVI

ES0157261019

Pharmaceuticals

Market Closed - BME 11:35:11 2024-05-16 am EDT 5-day change 1st Jan Change
85.75 EUR 0.00% Intraday chart for Laboratorios Farmaceuticos Rovi, S.A. +5.15% +42.44%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 819M 890M Sales 2025 * 907M 986M Capitalization 4.44B 4.83B
Net income 2024 * 176M 191M Net income 2025 * 212M 230M EV / Sales 2024 * 5.38 x
Net cash position 2024 * 38.22M 41.53M Net cash position 2025 * 147M 160M EV / Sales 2025 * 4.73 x
P/E ratio 2024 *
25.9 x
P/E ratio 2025 *
21.5 x
Employees 1,925
Yield 2024 *
1.31%
Yield 2025 *
1.56%
Free-Float 35.68%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Laboratorios Farmaceuticos Rovi, S.A.

1 week+5.34%
Current month+1.72%
1 month+3.50%
3 months+24.01%
6 months+69.80%
Current year+42.44%
More quotes
1 week
81.70
Extreme 81.7
86.95
1 month
77.75
Extreme 77.75
86.95
Current year
60.35
Extreme 60.35
86.95
1 year
37.96
Extreme 37.96
86.95
3 years
35.20
Extreme 35.2
86.95
5 years
17.50
Extreme 17.5
86.95
10 years
7.90
Extreme 7.9
86.95
More quotes
Managers TitleAgeSince
Chief Executive Officer - 93-12-31
Director of Finance/CFO - 99-12-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member - 94-12-31
Director of Finance/CFO - 99-12-31
Chief Executive Officer - 93-12-31
More insiders
Date Price Change Volume
24-05-16 85.75 0.00% 46,559
24-05-15 85.75 +1.60% 64,091
24-05-14 84.4 -0.18% 38,483
24-05-13 84.55 +1.14% 32,378
24-05-10 83.6 +2.51% 64,728

Delayed Quote BME, May 16, 2024 at 11:35 am EDT

More quotes
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows: - pharmaceutical products manufactured under contract (49%); - prescription pharmaceuticals (45%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.; - diagnostic products (6%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals. Net sales break down by source of revenue between sales of products (50.6%), sales of services (49.3%) and sales of licenses (0.1%). Net sales are distributed geographically as follows: Spain (33%), European Union (17.3%), OECD countries (45.9%) and other (3.8%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
85.75 EUR
Average target price
89.44 EUR
Spread / Average Target
+4.30%
Consensus

Quarterly revenue - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW